References
- 1. Abenavoli L, Falalyeyeva T, Boccuto L, Tsyryuk O, Kobyliak N. Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease. Pharmaceuticals. 2018;11(104):10.
- 2. Machado MV, Cortez-Pinto H. Non-alcoholic fatty liver disease: what the clinician needs to know. World J Gastroenterol. 2014; 20:12956-80.
- 3. Manzhalii E, Virchenko O, Falalyeyeva T, Beregova T, Stremmel W. Treatment efficacy of a probiotic preparation for non-alcoholic steatohepatitis: A pilot trial. J Dig Dis. 2017;18(12):698-703.
- 4. Neuman MG, French SW, French BA, Seitz HK, Cohen LB, Mueller S, et al. Alcoholic and non-alcoholic steatohepatitis. Exp Mol Pathol. 2014;97(3):492-510.
- 5. Kondro M, Mykhalchyshyn G, Bodnar P, Kobyliak N, Falalyeyeva T. Metabolic profile and morpho-functional state of the liver in rats with glutamate-induced obesity. Curr Issues Pharm. Med. Sci. 2013;2(4):379-81.
- 6. Drapkina OM, Korneeva OH, Ivashkin VT. [Treatment of nonalcoholic steatohepatitis in metabolic syndrome: focus on the essential phospholipids]. Lechaschiy Vrach. 2010;2:43-5.
- 7. Gerok V, Blum KhE. [Liver and biliary system]. M.: MEDpressinform; 2009:199.
- 8. Bataller R, Gao B. Liver fibrosis in alcoholic liver disease. Semin Liver Dis. 2015;35:146-56.
- 9. Weiler S, Merz M, Kullak-Ublick GA. Drug-induced liver injury: the dawn of biomarkers? F1000 Prime Rep. 2015;7:34.
- 10. Polunina TE, Maev IV. [Nonalcoholic fatty liver disease: epidemiology, pathogenesis, diagnosis, treatment]. Gastroenterologiya. 2012;1. Article in Russian
- 11. Voieikova DO, Kondro MM, Falaleyeva TM, Ostapchenko LI. Activity of enzymes of mitochondrial electron transport chain of rat hepatocytes under different steatosis. Research Journal of Pharmaceutical, Biological and Chemical Sciences. 2016;7(4):752-5.
- 12. Kondro M., Kobyliak N, Virchenko O, Falalyeyeva T, Beregova T, Bodnar P. Multiprobiotic therapy from childhood prevents the development of nonalcoholic fatty liver disease in adult monosodium glutamate-induced obese rats. Curr Issues Pharm. Med. Sci. 2014;2(4):243-5.
- 13. Baykova IE, Nikitin IG. [Drug liver]. Ross. Med. Zhurn. 2009;1. Article in Russian
- 14. Buyeverov AO, Yeshanu VS, Mayevskaya MV, Ivashkin VT. [Application of essential phospholipids in complex therapy of steatohepatitis of the mixed origin]. Klin. Persp. Gastroenterol. Hepatol. 2008;1:17-22. Article in Russian
- 15. Weismuller TJ, Lankisch TO. [Biliary diseases – new insights and developments]. Dtsch. Med. Wochenschr. 2011;136:713.
- 16. Kompanets I, Korotkiy A, Karpovets T, Ostapchenko L, Pilipenko S, Yankovskiy D. The interferon production and 2’,5’-oligoadenylatesynthetase activity in rat spleen lymphocytes at hypoacidity evoked by omeprazole injection and at administration of multiprobiotic «SYMBITER®». Curr Issues Pharm. Med. Sci. 2013;2(4):398-400.
- 17. Korotkyi O, Vovk A, Blokhina O, Dvorshchenko K, Falalyeyeva T, Abenavoli L et al. Effect of Chondroitin Sulfate on blood serum cytokine profile during Carrageenan-induced edema and Monoiodoacetate-induced osteoarthritis in rats. Rev Recent Clin Trials. 2018;2.
- 18. Khomeriki SG, Khomeriki NM. [Alcoholic liver disease: pathogenesis, morphological manifestations, differential diagnosis and pathogenetic approaches to therapy]. Gastroenterologiya. 2012;1. Article in Russian
- 19. Velkov VV. [Non-invasive biomarkers of fibrosis. Good-bye, biopsy?] Kliniko-laboratornyy consilium. 2009:30.